To investigate the association of serum copper and zinc with mortality from cancer and cardiovascular disease, the authors performed a case-control analysis of data obtained in a Dutch prospective follow-up study. Cancer (n = 64) and cardiovascular disease (n = 62) deaths and their matched controls were taken from a cohort of 10,532 persons examined in 1975-1978. Trace elements were measured in baseline serum samples, which had been stored during the six to nine years of follow-up. The adjusted risk of death from cancer and cardiovascular disease was about four times higher for subjects in the highest serum copper quintile (greater than 1.43 mg/liter) compared with those with normal levels. The excess mortality observed in subjects with low copper status suggests a U-shaped relation. No significant change in the risk of death from cancer and cardiovascular disease was found for subjects with low or high baseline levels of serum zinc. However, a protective effect of a high zinc status on the risk of cancer and cardiovascular disease is compatible with the data. For definitive conclusions, analysis of larger prospective data sets is recommended.

, , , , , , , , , , , , , , , , ,
hdl.handle.net/1765/5818
American Journal of Epidemiology
Erasmus MC: University Medical Center Rotterdam

Kok, F., van Duijn, C., de Wolf, F. A., Valkenburg, H., & Hofman, A. (1988). Serum copper and zinc and the risk of death from cancer and cardiovascular disease. American Journal of Epidemiology, 128, 352–359. Retrieved from http://hdl.handle.net/1765/5818